HALO Precision Diagnostics Appoints Thomas P. Slavin, M.D., as Chief Scientific Officer

Thomas P Slavin Md

Menlo Park, Calif., October 12, 2023 — HALO Precision Diagnostics™ (“HALO”), a leader
in early disease detection using precision diagnostics, today announced the appointment of
Thomas P. Slavin, M.D., as chief scientific officer.

Slavin is triple-board-certified in clinical genetics, molecular diagnostics, and pediatrics. He will
lead scientific operations and innovation at HALO, supporting the continued evolution of the
company’s robust imaging and precision diagnostic offerings across its growing network of
owned and partner precision diagnostic centers.

“Dr. Slavin is a highly respected clinical leader and scientist in genetic testing,” said Michael
Uhl, HALO chief executive officer. “We are fortunate to welcome him to HALO as we further
our mission to save lives with early disease detection.”

HALO’s molecular diagnostics approach, in combination with its proprietary precision
diagnostics platform, integrates advanced imaging to deliver comprehensive clinical insights for
early disease detection and treatment. HALO currently has clinically validated care pathways for
prostate cancer, breast cancer, and cardiovascular disease, as well as programs in development
for neurodegenerative and other life-threatening diseases.

“I have dedicated my career to bringing genetic solutions to patients through education, research,
and advocacy,” said Slavin. “HALO’s integrated approach to early disease detection is incredibly
unique and I look forward to contributing to the company’s life-saving work.”

Most recently, Slavin served as chief medical officer at Myriad Genetics. He is an expert in
hereditary cancer genetics and cancer screening and prevention, with extensive expertise in
oncology product commercialization and evaluating molecular diagnostic technologies.

Slavin is a renowned speaker and researcher in the field of medical genetics, publishing more
than 80 journal articles collectively evaluating genomic data from more than 500,000 patients.

Last month, HALO also announced the appointment of John Craighead, Ph.D., as chief operating
officer and chief financial officer.

Patient testimonial disclaimer: Each patient’s experience and recovery are unique and individual results vary. All testimonials are from real patients and may not reflect every patient’s experience. Testimonials are not intended to represent or guarantee that anyone will achieve the same or similar results.

Article Contents

Schedule a Consultation

Submit this form and we will contact you, usually within 24 hours, to answer your Prostate screening, diagnosis, and treatment questions.

We provide rapid, precise, and actionable results that create life-changing and life-saving individualized plans for patients.

Precision Diagnostics

Saving lives with early detection and personalized care.

Breast Health

Empowering women’s health through precision diagnostics.

Prostate Health

Early detection saves lives. HALO is setting the new standard for prostate care.